Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitals.
To assess whether physicians comply with American Society of Clinical Oncology (ASCO) guidelines for the use of CSFs, a prospective survey was performed in 15 Paris university hospitals involved in cancer treatment in 1997. If 45% of the prescriptions complied with the guidelines, primary prophylactic administration, which represented 52% of cases, did not comply with ASCO guidelines. These results suggested that primary prophylactic administration was one major clinical situation in which physicians could benefit from guidance to use a CSFs and that criteria defined by ASCO to allow primary prophylactic administration were not applied in clinical practice.
Debrix
I
I
Pharmacie-Toxicologie, Hopital Tenon, Paris, France.
Madelaine
I
I
Grenet
N
N
Roux
D
D
Bardin
C
C
Le Mercier
F
F
Fontan
J E
JE
Connor
O
O
Pointereau
A
A
Tilleul
P
P
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D004363:Drug Utilization; D005260:Female; D017408:Guidelines as Topic; D006397:Hematinics / Q000627:therapeutic use*; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D009503:Neutropenia / Q000139:chemically induced* / Q000517:prevention & control*; D010297:Paris; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors
D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors; D006397:Hematinics; D011994:Recombinant Proteins